UCLA Health researchers identified EPAC2 as a potential therapeutic target for Fragile X syndrome in preclinical work published in Neuron. The study, led by Carlos Portera-Cailliau and colleagues, used genetically engineered mice lacking Fmr1 and found that blocking EPAC2 restored abnormal brain activity patterns and improved multiple behavioral symptoms linked to Fragile X. The findings continue a long search for effective, mechanism-based treatments in Fragile X, where multiple clinical trials have not yielded a disease-specific therapy. EPAC2 is presented as a synaptic and signaling node potentially tied to excitatory/inhibitory balance disruptions that characterize Fragile X. Because Fragile X is a monogenic neurodevelopmental disorder affecting about one in 2,000 boys, a defined target can accelerate translational efforts if suitable inhibitors or biologics can be developed and safely dosed. The next steps will likely include mapping EPAC2 pathway effects across relevant neuronal populations and evaluating pharmacologic feasibility—whether EPAC2 inhibition can reproduce the mouse benefits in more clinically relevant models.